On this page
Quick Reference
Overview and Recommendations
Background
- •Gastric cancer is the fifth most common cancer worldwide and the third leading cause of cancer death. Surgical resection with curative intent is the mainstay for localized disease, with the goal of R0 resection and adequate lymphadenectomy. The management is stage-dependent: early gastric cancer (T1) may be amenable to endoscopic resection or limited surgery, while locally advanced disease (T2-4 or N+) requires D2 gastrectomy with perioperative chemotherapy.
- •The paradigm has shifted from surgery alone to multimodality therapy. In the West, perioperative chemotherapy (MAGIC trial: ECF; FLOT regimen) improved overall survival (HR 0.75). In Asia, adjuvant S-1 (ACTS-GC) and neoadjuvant DOS followed by S-1 (PRODIGY) have become standards. The four pillars of modern management are adequate surgery, perioperative systemic therapy, lymphadenectomy, and ERAS.
- •Key surgical approaches include distal gastrectomy, total gastrectomy, and proximal gastrectomy. Lymphadenectomy extent (D1 vs D2) impacts outcomes: D2 dissection improves disease-specific survival compared with D1 (HR 0.807; NNT = 10). At least 16 lymph nodes should be assessed for adequate staging.
- •Laparoscopic gastrectomy has been validated in multiple randomized controlled trials (KLASS-01, KLASS-02, LOGICA, CLASS-02) as oncologically noninferior to open surgery, with equivalent 5-year overall survival and fewer early and late complications. Robotic gastrectomy offers technical advantages in lymph node dissection, particularly in narrow spaces.
- •Function-preserving techniques are emerging for early gastric cancer. Pylorus-preserving gastrectomy (PPG) for middle-third cT1N0 tumors reduces bile reflux, gallstone formation, and nutritional deficiencies. Sentinel node navigation surgery (LSNNS) allows stomach preservation in 74.8% of patients with cT1N0 tumors ≤3 cm, with 3-year disease-specific survival of 99.1%.
- •Enhanced recovery after surgery (ERAS) protocols have become standard of care. ERAS shortens hospital stay by ~1.8 days, reduces overall complications (OR 0.63), and improves 3-year overall survival in stage III gastric cancer (; HR 0.57). Core elements include prehabilitation, opioid-sparing analgesia, early oral feeding, and selective omission of abdominal drains.
Evaluation
- •Suspect gastric cancer in patients with dyspepsia, weight loss, early satiety, iron deficiency anemia, or hematemesis. Upper endoscopy with biopsy is the diagnostic gold standard; obtain multiple biopsies from the tumor and surrounding mucosa.
- •Stage with contrast-enhanced CT of chest, abdomen, and pelvis to assess T stage, nodal involvement, and distant metastases. Endoscopic ultrasound (EUS) is essential for accurate T and N staging, especially for early tumors where endoscopic resection or limited surgery may be considered.
- •Assess HER2, MSI, and PD-L1 status on biopsy specimens to guide perioperative and systemic therapy decisions. HER2-positive tumors benefit from trastuzumab; MSI-high tumors are highly responsive to immune checkpoint inhibitors.
- •For early gastric cancer (cT1N0), evaluate eligibility for endoscopic resection (differentiated type, ≤2 cm, no ulceration) or sentinel node navigation (tumor ≤3 cm). If not eligible, proceed to laparoscopic gastrectomy with D1+ lymphadenectomy.
- •For locally advanced disease (cT2-4 or N+), multidisciplinary discussion is essential. Consider neoadjuvant chemotherapy: FLOT (docetaxel 50 mg/m², oxaliplatin 85 mg/m², leucovorin 200 mg/m², 5-FU 2600 mg/m² as 24h infusion) every 2 weeks for 4 cycles in the West; DOS (docetaxel 50 mg/m², oxaliplatin 100 mg/m², S-1 80-120 mg/day) in Asia.
- •Assess patient fitness for surgery: performance status (ECOG 0-2), nutritional status (NRS-2002), and frailty (Geriatric 8 score). Use preoperative risk stratification tools such as the Comprehensive Inflammatory-Metabolic Index (CIMI) to predict complications (AUC 0.748).
- •Preoperative imaging should include assessment of left gastric vein (LGV) anatomy on CT. Type C LGV (dorsal to splenic artery) predicts a 17.9% risk of postoperative pancreatic fistula (POPF) vs 1.7% for other types.
- •Consider staging laparoscopy for patients at high risk of peritoneal metastases: signet ring histology, diffuse type, advanced T stage (T3/T4), or suspicious findings on CT. Laparoscopy can detect occult peritoneal disease and avoid unnecessary laparotomy.
- •For metastatic disease (stage IV), surgery is reserved for palliation of obstruction or bleeding. Systemic therapy is primary; trastuzumab plus chemotherapy for HER2-positive, nivolumab plus chemotherapy for PD-L1 CPS ≥5, and apatinib for third-line therapy.
- •Also consider fertility preservation in young patients with early gastric cancer. Pylorus-preserving gastrectomy or sentinel node navigation may be appropriate to maintain reproductive potential and long-term quality of life.
Management
- •For early gastric cancer (cT1N0, ≤3 cm): offer laparoscopic sentinel node navigation surgery (LSNNS) if available; stomach preservation achieved in 74.8% of patients. If not eligible, perform laparoscopic distal gastrectomy with D1+ lymphadenectomy. For middle-third tumors, consider pylorus-preserving gastrectomy (PPG) to reduce bile reflux and nutritional deficiencies.
- •For locally advanced gastric cancer (cT2-4 or N+): administer perioperative chemotherapy. In the West, use FLOT (docetaxel 50 mg/m², oxaliplatin 85 mg/m², leucovorin 200 mg/m², 5-FU 2600 mg/m² as 24h infusion) every 2 weeks for 4 cycles before and 4 cycles after surgery. In Asia, neoadjuvant DOS (docetaxel 50 mg/m², oxaliplatin 100 mg/m², S-1 80-120 mg/day) followed by D2 gastrectomy and adjuvant S-1 for 1 year.
- •Perform D2 lymphadenectomy (removal of perigastric nodes plus nodes along celiac axis, splenic artery, common hepatic artery, and left gastric artery). Aim for at least 16 lymph nodes. Use indocyanine green (ICG) fluorescence to improve nodal yield, especially after neoadjuvant therapy (mean difference 9.3 nodes) and in obese patients (mean difference 10.94 nodes).
- •For patients who undergo upfront surgery without neoadjuvant therapy and have T3+ or node-positive disease: administer adjuvant chemoradiation (45 Gy with 5-FU/leucovorin) per INT-0116. However, after D2 dissection, adjuvant chemotherapy alone (S-1 or SOX) is preferred based on CRITICS and ARTIST 2 data.
- •For stage III node-positive disease after D2: use S-1 (80-120 mg/day, 4 weeks on/2 weeks off for 1 year) plus docetaxel (JACCRO GC-07) to improve 3-year relapse-free survival from 50% to 66% (NNT=6). Alternatively, SOX (S-1 80-120 mg/day days 1-14, oxaliplatin 130 mg/m² day 1, every 3 weeks for 6 months) is effective (ARTIST 2).
- •For HER2-positive advanced disease: add trastuzumab (8 mg/kg loading, then 6 mg/kg every 3 weeks) to chemotherapy (capecitabine/cisplatin or 5-FU/oxaliplatin). After trastuzumab failure, anbenitamab plus chemotherapy improves PFS (HR 0.25) and OS (HR 0.29).
- •For MSI-high advanced disease: use pembrolizumab or nivolumab plus chemotherapy. Anti-PD-1 regimens yield OS HR 0.34 in MSI-high vs 0.85 in MSS (P interaction = 0.003).
- •Intraoperative management: use a pancreas-contactless technique to reduce POPF (from 7.6% to 0% in open gastrectomy). Perform intraoperative air-leak test for anastomotic integrity. Have a low threshold for conversion to open if bleeding is not rapidly controlled laparoscopically.
- •Postoperative ERAS: initiate early oral feeding (clear liquids on POD 1, soft diet by POD 3-4), multimodal opioid-sparing analgesia (subcostal TAP block, acetaminophen, COX-2 inhibitors), early mobilization, and selective omission of abdominal drains. Discharge criteria: tolerating oral intake, pain controlled with oral analgesics, afebrile, ambulating independently.
- •Monitor for complications: pancreatic fistula (POPF) - manage with drainage, nil per os, parenteral nutrition, somatostatin analogues; anastomotic leak - endoscopic stenting or percutaneous drainage; reoperation for large defects. Use preoperative LGV anatomy to stratify POPF risk.
- •Avoid: non-dihydropyridine CCBs (diltiazem, verapamil) - exacerbate gastroparesis; routine abdominal drainage - increases complications (OR 0.53 for omission); routine radiotherapy after D2 dissection - no benefit (ARTIST 2); ELFE, FAMTX, or FEMTX regimens - no survival benefit; adjuvant nivolumab/ipilimumab for ypN+/R1 after neoadjuvant chemo - inferior to chemotherapy (VESTIGE).
- •Refer to medical oncology for perioperative therapy and management of advanced disease. Refer to radiation oncology if adjuvant chemoradiation is indicated (inadequate lymphadenectomy or R1 resection). Refer to palliative care for symptom management in advanced disease.
- •For young patients with early gastric cancer: consider pylorus-preserving gastrectomy or sentinel node navigation to preserve fertility and long-term quality of life. Discuss fertility preservation options preoperatively.
- •Long-term surveillance: clinical follow-up with history, physical exam, and contrast-enhanced CT every 3-6 months for first 2 years, then every 6-12 months. Endoscopy as indicated for symptoms. Monitor nutritional status with NRS-2002 every 2 weeks for first 3 months; oral nutritional supplements if needed, target 25-30 kcal/kg/day and protein 1.0-1.5 g/kg/day.
Board Review — High Yield
- •MAGIC trial, Perioperative ECF chemotherapy improved overall survival (HR 0.75) compared to surgery alone for resectable gastric cancer.
- •D2 lymphadenectomy, Improves disease-specific survival over D1 (HR 0.807); at least 16 lymph nodes required for adequate staging.
- •KLASS-01, Laparoscopic distal gastrectomy noninferior to open for stage I gastric cancer (5-year OS 94.2% vs 93.3%).
- •S-1 plus docetaxel (JACCRO GC-07), For stage III after D2, improves 3-year RFS from 50% to 66% (NNT=6).
- •ERAS (GISSG1901), Reduces complications, hospital stay, and improves 3-year survival in stage III gastric cancer (HR 0.57).
- •Sentinel node navigation (SENORITA), For cT1N0 tumors ≤3 cm, detection rate 97.5%, accuracy 99%; stomach preservation in 74.8%.
- •Pylorus-preserving gastrectomy (KLASS-04), For middle-third early gastric cancer, reduces bile reflux, gallstone formation, and nutritional deficiencies.
- •ICG fluorescence, Increases lymph node yield by 6.9 nodes (mean), especially after neoadjuvant therapy and in obese patients.
- •CRITICS trial, After D2, adjuvant chemotherapy alone superior to chemoradiation (5-year OS 57.9% vs 45.5%; adjusted HR 1.62).
- •VESTIGE trial, Nivolumab/ipilimumab inferior to chemotherapy for ypN+/R1 after neoadjuvant chemo (median DFS 11.4 vs 20.8 months; HR 1.55).
Deep Dive — Evidence Details
Indications by Stage
- ▸D2 gastrectomy + perioperative chemotherapy is standard for locally advanced disease.
- ▸LSNNS is a stomach-preserving option for select early gastric cancer.
Surgical management of is stage-dependent. For early gastric cancer (cT1N0, ≤3 cm), laparoscopic sentinel node navigation surgery (LSNNS) allows stomach preservation in 81% of patients, with 3-year disease-specific survival of 99.1% vs. 99.5% for standard [18]A1b. For locally advanced (T2-4, N+), D2 gastrectomy with perioperative chemotherapy is standard. The MAGIC trial established perioperative ECF ( , , fluorouracil) improving OS (HR 0.75) [7]A1b. PRODIGY showed neoadjuvant DOS ( , , S-1) followed by D2 surgery and adjuvant S-1 improved PFS (HR 0.70) [10]A1b[13]A1b. After upfront surgery, adjuvant chemoradiation (INT-0116) reduces relapse (HR 1.51) [14]A1b. For metastatic disease, surgery is palliative only. Pearl: For locally advanced gastric cancer, D2 gastrectomy with perioperative chemotherapy (MAGIC-style ECF/X or PRODIGY-style DOS) is the evidence-based standard; adjuvant chemoradiation is an alternative for patients who did not receive neoadjuvant therapy, but after D2 dissection, adjuvant chemotherapy alone may be preferred based on CRITICS data.
Operative Techniques
- ▸Laparoscopic D2 gastrectomy is noninferior to open with fewer complications.
- ▸ICG fluorescence improves nodal yield, especially in neoadjuvant/obese patients.
Laparoscopic gastrectomy is noninferior to open for early and locally advanced disease. KLASS-01 (stage I) showed 5-year OS 94.2% vs. 93.3% [24]A1b. KLASS-02 (locally advanced) showed 3-year RFS 80.3% vs. 81.3% (noninferior) with fewer complications [21]A1b. D2 lymphadenectomy (removal of perigastric + celiac, splenic, hepatic, and left gastric nodes) is standard for advanced disease, with ≥16 nodes assessed [20]B2a[26]D5. Pylorus-preserving gastrectomy (PPG) is indicated for cT1N0M0 middle-third tumors ≥4 cm from pylorus, reducing gallstones and bile reflux [32]A1b. Sentinel node navigation (LSNNS) for early cancer (≤3 cm) allows stomach preservation in 81%, but 3-year DFS did not meet noninferiority (91.8% vs. 95.5%) [18]A1b. ICG fluorescence lymphography retrieves ~7 more nodes (mean difference 6.91, 95% CI 5.47-8.35) [30]A1a. Pearl: For patients with resectable gastric cancer, laparoscopic distal gastrectomy with D2 lymphadenectomy is the evidence-based standard for both early and locally advanced disease, offering equivalent oncologic outcomes and fewer complications than open surgery.
Fertility-Sparing Surgery
- ▸PPG preserves pyloric function and reduces nutritional deficiencies.
- ▸Indicated for cT1N0M0 middle-third tumors ≥4 cm from pylorus.
For young patients with early , function-preserving approaches minimize long-term morbidity. Pylorus-preserving (PPG) is indicated for cT1N0M0 middle-third tumors ≥4 cm from pylorus [32]A1b. By preserving the hepatic branch of the vagus nerve and infrapyloric vessels, PPG reduces gallstone formation, bile reflux, and postoperative nutritional deficiencies (KLASS-04 trial) [32]A1b. These benefits are critical for preserving fertility and pregnancy outcomes. PPG is technically demanding; advances in minimally invasive surgery and ICG imaging facilitate safe implementation [32]A1b. If postoperative pathology reveals advanced disease, standard adjuvant therapy is sufficient without additional resection [32]A1b. Pearl: For young patients with cT1N0M0 gastric cancer in the middle third, pylorus-preserving gastrectomy should be the preferred function-preserving approach, as it reduces postoperative nutritional deficiencies and bile reflux, supporting long-term quality of life and potentially fertility.
Sentinel Lymph Node Mapping
- ▸SLN mapping is highly accurate for cT1-2 tumors <4 cm.
- ▸If frozen section is negative, sentinel basin dissection alone is safe.
Sentinel node (SLN) mapping uses dual tracer (blue dye + radioactive colloid or ICG) injected submucosally at four points around the tumor. Eligibility: cT1 or cT2 adenocarcinomas <4 cm [55]B2b. Detection rate: 97.5%; accuracy for metastasis: 99% [55]B2b. False-negative rate is low (4/397), mostly in pT2 or >4 cm tumors [55]B2b. Intraoperative frozen section (single-section HE) detects macrometastasis with 0% failure [62]C4. If frozen section is negative, sentinel basin dissection alone is safe; if positive, proceed to standard D2 gastrectomy [62]C4. In SENORITA, LSNNS achieved stomach preservation in 74.8% [58]A1b. Metastasis to non-sentinel basins with tumor-free sentinel basins occurs in only 0.4% [60]C4. Pearl: For early gastric cancer (cT1N0M0, tumor <4 cm), sentinel node mapping with dual tracer yields >97% detection and 99% accuracy; if frozen section is negative, sentinel basin dissection alone is safe, but if positive, proceed to standard D2 gastrectomy.
| Parameter | Value | Source |
|---|---|---|
| Detection rate | 97.5% (387/397) | [55]B2b |
| Sensitivity for metastasis | 93% (53/57) | [55]B2b |
| Accuracy | 99% (383/387) | [55]B2b |
| False-negative rate | 7% (4/57) | [55]B2b |
| Metastasis to non-sentinel basins (sentinel negative) | 0.4% (1/237) | [60]C4 |
| Stomach preservation success (SENORITA) | 74.8% (193/258) | [58]A1b |
Adjuvant Therapy Triggers
- ▸S-1 +/- docetaxel is standard for Asian D2-resected stage II/III.
- ▸Adjuvant radiotherapy is not indicated after D2 dissection.
Postoperative therapy is guided by pathology. For Asian patients with D2-resected stage II/III, S-1 monotherapy (80-120 mg/day, 4 weeks on/2 weeks off for 1 year) is standard (ACTS-GC, 5-year OS 71.7% vs. 61.1%) [77]A1b. For node-positive stage III, adding to S-1 improves 3-year RFS from 50% to 66% (HR 0.632; NNT=6) [12]A1b. SOX (S-1 plus 130 mg/m² q3 weeks) for 6 months is an alternative [73]A1b. For Western patients, perioperative FLOT or postoperative chemoradiation (45 Gy with FU/LV) is standard [14]A1b. After D2 surgery, chemotherapy alone is preferred (CRITICS: 5-year OS 57.9% vs. 45.5% with chemoradiation) [5]A1b. Do not use adjuvant nivolumab/ipilimumab in ypN+/R1 patients (VESTIGE: inferior DFS) [19]B2b. Pearl: For patients with D2-resected, node-positive stage III gastric cancer, the addition of docetaxel to S-1 yields a 3-year relapse-free survival benefit of 16 percentage points (NNT = 6) and should be considered the new standard in Asia, while routine radiotherapy after D2 dissection is not supported by current evidence.
Intraoperative Considerations and Complications
- ▸Pancreas-contactless technique dramatically reduces POPF.
- ▸Preoperative CT LGV anatomy predicts POPF risk.
Intraoperative bleeding is the most common reason for conversion. D2+PAND adds ~230 mL blood loss [85]A1b. Pancreatic fistula (POPF) risk is predicted by left gastric vein (LGV) anatomy: Type C (dorsal to splenic artery) carries 17.9% POPF vs. 1.7% for other types [93]C4. A pancreas-contactless technique reduces POPF from 7.6% to 0% [94]B3b. Anastomotic leak rates: 10.3% after robot-assisted total gastrectomy vs. 6.1% laparoscopic [97]B3b. Preoperative risk tools: Comprehensive Inflammatory-Metabolic Index (CIMI) predicts complications with AUC 0.748 [83]A1b; frailty+sarcopenia in elderly predicts 30-day complications (OR 2.73) [91]C4. Conversion criteria: uncontrolled bleeding, inability to achieve adequate dissection, suspicion of T4b invasion. Pearl: Preoperative CT assessment of left gastric vein anatomy (Type C) identifies patients at highest risk for pancreatic fistula, and routine use of a pancreas-contactless technique can reduce POPF to near zero, a simple, reproducible maneuver that avoids a morbid complication.
Postoperative Recovery and ERAS
- ▸ERAS reduces complications, hospital stay, and improves survival in stage III.
- ▸Avoid routine abdominal drains but consider selective omission.
Enhanced Recovery After Surgery (ERAS) is standard for surgery. Meta-analysis of 13 RCTs (n=1,915) shows ERAS shortens hospital stay (MD -1.82 days), reduces complications (OR 0.63), and accelerates flatus, oral intake, and ambulation [102]A1a. Key elements: prehabilitation for frail elderly (Geriatric 8 ≤14) reduces 30-day complications from 28.7% to 17.2% [107]A1b; multimodal opioid-sparing analgesia (subcostal TAP block, acetaminophen, COX-2 inhibitors) reduces fentanyl consumption by 500 μg over 72 hours [109]A1b; early oral feeding is safe [104]A1a; avoid routine abdominal drains (reduces complications, OR 0.53) [118]A1a, but selective omission is prudent (ADIGE: increased reoperation from 7.7% to 15%) [111]A1b. The GISSG1901 trial showed ERAS improves 3-year OS (86.56% vs. 80.11%) and DFS in stage III disease [110]A1b. Pearl: ERAS is not merely about faster discharge, the GISSG1901 trial showed it improves 3-year survival in stage III gastric cancer (NNT ≈ 7 to prevent one death), likely through reduced complications, attenuated inflammation, and earlier adjuvant chemotherapy [110]A1b.
| Component | Evidence Summary | Key Reference |
|---|---|---|
| Prehabilitation (frail patients) | Reduces 30-day complications from 28.7% to 17.2% | [107]A1b |
| Multimodal opioid-sparing analgesia | Reduces pain scores and fentanyl consumption by 500 μg/72 h | [109]A1b |
| Early oral feeding | Reduces hospital stay by 1.82 days; safe without increased complications | [104]A1a |
| Avoidance of routine drainage | Faster recovery, fewer complications (OR 0.53); ADIGE trial shows increased reintervention risk | [118]A1a[111]A1b |
| Psychosocial intervention | Improves 2-year DFS (HR 0.58) and OS (HR 0.52) | [106]A1b |
Outcomes by Stage and Approach
- ▸Adjuvant SOX improves 3-year DFS in stage II-III (NNT=11).
- ▸Nivolumab+chemo for CPS≥5 yields 5-year OS benefit (NNT=10).
For resectable stage II-III, adjuvant SOX (S-1 + 130 mg/m² q3 weeks) for 6 months yields 3-year DFS 74.3% vs. 64.8% with S-1 alone (NNT=11) [73]A1b. Neoadjuvant DOS improves PFS (HR 0.70) [10]A1b. For advanced/metastatic disease, first-line + chemotherapy in PD-L1 CPS≥5 gives 5-year OS 16% vs. 6% (HR 0.71; NNT=10) [120]A1b. In HER2+ disease after trastuzumab failure, anbenitamab + chemo improves PFS (HR 0.25) and OS (HR 0.29) [121]A1b. MSI-high status predicts exceptional immunotherapy benefit (OS HR 0.34) [128]A1a. Laparoscopic vs. open gastrectomy shows equivalent oncologic outcomes: LOGICA trial reported 1-year OS 76% vs. 78%, R0 95% both, lymph node yield 29 both [16]A1b. Pearl: Nodal response (ypN0) after preoperative therapy is a stronger predictor of survival than primary tumor response; patients with ypN+ disease have poor outcomes regardless of postoperative therapy [79]B3b.
References
- [1]
Ajani JA, Bentrem DJ, Besh S et al.. “Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines.” Journal of the National Comprehensive Cancer Network : JNCCN (2013). PMID: 23667204 ↗
L1GUIDELINECited in: Indications by Stage - [2]
Nitti D, Wils J, Dos Santos JG et al.. “Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG.” Annals of oncology : official journal of the European Society for Medical Oncology (2005). PMID: 16293676 ↗
L1SR_MA_RCTCited in: Indications by Stage, Adjuvant Therapy Triggers (Post-op Risk Criteria), Outcomes by Stage and Approach - [3]
Shen L, Shan YS, Hu HM et al.. “Management of gastric cancer in Asia: resource-stratified guidelines.” The Lancet. Oncology (2013). PMID: 24176572 ↗
L1GUIDELINECited in: Indications by Stage - [4]
Mocellin S, Nitti D. “Lymphadenectomy extent and survival of patients with gastric carcinoma: a systematic review and meta-analysis of time-to-event data from randomized trials.” Cancer treatment reviews (2015). PMID: 25814393 ↗
L1SR_MA_RCTCited in: Indications by Stage - [5]
de Steur WO, van Amelsfoort RM, Hartgrink HH et al.. “Adjuvant chemotherapy is superior to chemoradiation after D2 surgery for gastric cancer in the per-protocol analysis of the randomized CRITICS trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2020). PMID: 33227408 ↗
L1RCTCited in: Indications by Stage, Adjuvant Therapy Triggers (Post-op Risk Criteria) - [6]
Fazio N, Biffi R, Maibach R et al.. “Preoperative versus postoperative docetaxel-cisplatin-fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2015). PMID: 26712905 ↗
L1RCTCited in: Indications by Stage, Adjuvant Therapy Triggers (Post-op Risk Criteria) - [7]
Smyth EC, Nyamundanda G, Cunningham D et al.. “A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the MAGIC trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2018). PMID: 30481267 ↗
L1RCTCited in: Indications by Stage, Adjuvant Therapy Triggers (Post-op Risk Criteria) - [8]
Okines AF, Thompson LC, Cunningham D et al.. “Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2012). PMID: 23233651 ↗
L1RCTCited in: Indications by Stage - [9]
Kwee RM, Kwee TC. “Imaging in local staging of gastric cancer: a systematic review.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2007). PMID: 17513817 ↗
L2SR_COHORTCited in: Indications by Stage - [10]
Kang YK, Yook JH, Park YK et al.. “PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 34133211 ↗
L1RCTCited in: Indications by Stage, Adjuvant Therapy Triggers (Post-op Risk Criteria), Outcomes by Stage and Approach - [11]
Rau B, Lang H, Koenigsrainer A et al.. “Effect of Hyperthermic Intraperitoneal Chemotherapy on Cytoreductive Surgery in Gastric Cancer With Synchronous Peritoneal Metastases: The Phase III GASTRIPEC-I Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37906724 ↗
L1RCTCited in: Indications by Stage - [12]
Yoshida K, Kodera Y, Kochi M et al.. “Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2019). PMID: 30925125 ↗
L1RCTCited in: Indications by Stage, Adjuvant Therapy Triggers (Post-op Risk Criteria), Postoperative Recovery and ERAS - [13]
Kang YK, Kim HD, Yook JH et al.. “Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer: Updated Overall Survival Outcomes From Phase III PRODIGY.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 38996201 ↗
L1RCTCited in: Indications by Stage, Adjuvant Therapy Triggers (Post-op Risk Criteria) - [14]
Smalley SR, Benedetti JK, Haller DG et al.. “Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2012). PMID: 22585691 ↗
L1RCTCited in: Indications by Stage, Adjuvant Therapy Triggers (Post-op Risk Criteria), Outcomes by Stage and Approach - [15]
Li C, Tian Y, Zheng Y et al.. “Pathologic Response of Phase III Study: Perioperative Camrelizumab Plus Rivoceranib and Chemotherapy Versus Chemotherapy for Locally Advanced Gastric Cancer (DRAGON IV/CAP 05).” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 39383487 ↗
L1RCTCited in: Indications by Stage, Outcomes by Stage and Approach - [16]
van der Veen A, Brenkman HJF, Seesing MFJ et al.. “Laparoscopic Versus Open Gastrectomy for Gastric Cancer (LOGICA): A Multicenter Randomized Clinical Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 34581617 ↗
L1RCTCited in: Indications by Stage, Operative Techniques, Outcomes by Stage and Approach - [17]
Hu Y, Huang C, Sun Y et al.. “Morbidity and Mortality of Laparoscopic Versus Open D2 Distal Gastrectomy for Advanced Gastric Cancer: A Randomized Controlled Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2016). PMID: 26903580 ↗
L1RCTCited in: Indications by Stage, Operative Techniques, Outcomes by Stage and Approach - [18]
Kim YW, Min JS, Yoon HM et al.. “Laparoscopic Sentinel Node Navigation Surgery for Stomach Preservation in Patients With Early Gastric Cancer: A Randomized Clinical Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 35324317 ↗
L1RCTCited in: Indications by Stage, Operative Techniques, Intraoperative Considerations and Complications - [19]
Lordick F, Mauer ME, Stocker G et al.. “Adjuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): European Organisation of Research and Treatment of Cancer (EORTC) 1707 VESTIGE study.” Annals of oncology : official journal of the European Society for Medical Oncology (2024). PMID: 39542422 ↗
L2RCT_PHASE2Cited in: Indications by Stage, Adjuvant Therapy Triggers (Post-op Risk Criteria), Outcomes by Stage and Approach - [20]
Coburn N, Cosby R, Klein L et al.. “Staging and surgical approaches in gastric cancer: A systematic review.” Cancer treatment reviews (2017). PMID: 29275224 ↗
L2SR_COHORTCited in: Indications by Stage, Operative Techniques - [21]
Hyung WJ, Yang HK, Park YK et al.. “Long-Term Outcomes of Laparoscopic Distal Gastrectomy for Locally Advanced Gastric Cancer: The KLASS-02-RCT Randomized Clinical Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020). PMID: 32816629 ↗
L1RCTCited in: Operative Techniques - [22]
Ajani JA, Winter K, Okawara GS et al.. “Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2006). PMID: 16921048 ↗
L2NON_RANDOMIZED_TRIALCited in: Operative Techniques - [23]
Liu F, Huang C, Xu Z et al.. “Morbidity and Mortality of Laparoscopic vs Open Total Gastrectomy for Clinical Stage I Gastric Cancer: The CLASS02 Multicenter Randomized Clinical Trial.” JAMA oncology (2020). PMID: 32815991 ↗
L1RCTCited in: Operative Techniques, Intraoperative Considerations and Complications - [24]
Kim HH, Han SU, Kim MC et al.. “Effect of Laparoscopic Distal Gastrectomy vs Open Distal Gastrectomy on Long-term Survival Among Patients With Stage I Gastric Cancer: The KLASS-01 Randomized Clinical Trial.” JAMA oncology (2019). PMID: 30730546 ↗
L1RCTCited in: Operative Techniques - [25]
Ding PA, Yang S, Meng LJ et al.. “A Multimodal Deep Learning Model for Preoperative Prediction of Postoperative Complications in Gastric Cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2026). PMID: 42463045 ↗
L4PROSPECTIVE_COHORTCited in: Operative Techniques - [26]
Badgwell B. “Multimodality Therapy of Localized Gastric Adenocarcinoma.” Journal of the National Comprehensive Cancer Network : JNCCN (2016). PMID: 27697984 ↗
L5NARRATIVE_REVIEWCited in: Operative Techniques - [27]
Ly QP, Sasson AR. “Modern surgical considerations for gastric cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2008). PMID: 18926098 ↗
L5NARRATIVE_REVIEWCited in: Operative Techniques - [28]
Teh SH, Uong S, Lin TY et al.. “Clinical Outcomes Following Regionalization of Gastric Cancer Care in a US Integrated Health Care System.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 34339289 ↗
L2PROSPECTIVE_COHORTCited in: Operative Techniques - [29]
Nasri S, Laamiri G, Ben Safta A et al.. “Five-year survival after minimally invasive versus open gastrectomy: A meta-analysis of randomized controlled trials with trial sequential analysis.” Surgical oncology (2026). PMID: 42364595 ↗
L1SR_MA_RCTCited in: Operative Techniques - [30]
Deidda L, Pisanu A, Ielpo B et al.. “Guiding role of indocyanine green fluorescence lymphography compared to standard techniques in lymphadenectomy for gastric cancer during minimally invasive surgery: a systematic review and meta-analysis.” Updates in surgery (2026). PMID: 42223895 ↗
L1SR_MA_RCTCited in: Operative Techniques, Sentinel Lymph Node Mapping - [31]
Kim HH, Han SU, Kim MC et al.. “Long-term results of laparoscopic gastrectomy for gastric cancer: a large-scale case-control and case-matched Korean multicenter study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2014). PMID: 24470012 ↗
L3CASE_CONTROLCited in: Operative Techniques - [32]
Kim SH, Lee HJ. “Pylorus-Preserving Gastrectomy for Gastric Cancer: Current Evidence and Future Directions.” Annals of gastroenterological surgery (2026). PMID: 42495678 ↗
L1RCTCited in: Operative Techniques, Fertility-Sparing Surgery, Sentinel Lymph Node Mapping - [33]
Zhang Y, Lao LST, Shen X et al.. “Perioperative outcomes of a novel laparoscopic-like "3-arm + 2-port" model in robot-assisted distal gastrectomy in patients with resectable, non-metastatic gastric cancer: a randomized controlled trial.” Journal of robotic surgery (2026). PMID: 42484711 ↗
L1RCTCited in: Operative Techniques, Fertility-Sparing Surgery, Intraoperative Considerations and Complications - [34]
Das P, Jiang Y, Lee JH et al.. “Multimodality approaches to localized gastric cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2010). PMID: 20410334 ↗
L5OTHERCited in: Operative Techniques - [35]
Lin R, Wei S. “Comparison of the efficacy and safety of single-incision versus multi-port laparoscopic D2 lymphadenectomy for locally advanced gastric cancer: a systematic review and meta-analysis.” Journal of gastrointestinal oncology (2026). PMID: 42169910 ↗
L1SR_MA_RCTCited in: Operative Techniques - [36]
Cui Y, Zhang T, Du Y et al.. “Photodynamic therapy: research progress and paradigm evolution from mechanism innovation to clinical breakthrough in cancers.” Medical gas research (2026). PMID: 42157432 ↗
L1RCTCited in: Operative Techniques - [37]
Miao L, She Y, Wang Y et al.. “The incidence of gastric neoplastic lesions in autoimmune gastritis: a systematic review and meta-analysis.” Surgical endoscopy (2026). PMID: 42493616 ↗
L2SR_COHORTCited in: Fertility-Sparing Surgery - [38]
Mandrina M, Gevorkyan T, Zvezda S et al.. “Correction: Gastric cancer survival prediction using artificial intelligence models based on electronic health records: a systematic review and meta-analysis.” Frontiers in digital health (2026). PMID: 42495053 ↗
L2SR_COHORTCited in: Fertility-Sparing Surgery - [39]
Wang GQ, Li SR, Li SY et al.. “Metabolic Syndrome, Component Burden, and Incident Gastric Cancer Risk: A Prospective Cohort Study in the UK Biobank.” Cancer research communications (2026). PMID: 42490138 ↗
L2PROSPECTIVE_COHORTCited in: Fertility-Sparing Surgery - [40]
Wen T, Zhang X, Zhang X et al.. “Perioperative nutritional support is associated with attenuated early postoperative albumin decline after gastrectomy for gastric cancer: a retrospective cohort study and machine learning prediction model.” Frontiers in medicine (2026). PMID: 42487944 ↗
L2PROSPECTIVE_COHORTCited in: Fertility-Sparing Surgery - [41]
Zheng G, Chai X, Jin P et al.. “Multiscale Spatial Fusion Feature-Driven Characterization of Gastric Cancer Invasive Margins: A Multicenter Cohort Study for Preoperative Accurate Differentiation Between T4a and T4b Subtypes.” Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2026). PMID: 42474705 ↗
L2PROSPECTIVE_COHORTCited in: Fertility-Sparing Surgery - [42]
Seyyedsalehi MS, Vrtev A, Lanza M et al.. “Occupational exposure to polycyclic aromatic hydrocarbons and the risk of upper gastrointestinal cancers: a systematic review and meta-analysis of cohort studies.” European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) (2026). PMID: 42467956 ↗
L2SR_COHORTCited in: Fertility-Sparing Surgery - [43]
Huang Z, Gu L, Shi Y et al.. “Association of Helicobacter pylori infection with the correa cascade: a single-center, retrospective cohort study.” Frontiers in cellular and infection microbiology (2026). PMID: 42488421 ↗
L3RETROSPECTIVE_COHORTCited in: Fertility-Sparing Surgery - [44]
Han YP, Yu HL, Wei YL et al.. “Construction and validation of a nomogram for predicting pathological upgrading/progression of gastric low-grade intraepithelial neoplasia.” Frontiers in medicine (2026). PMID: 42482913 ↗
L3COHORTCited in: Fertility-Sparing Surgery - [45]
Shi Y, Zhang J, Gu J et al.. “Dynamic Changes in Circulating and Tissue Biomarkers and Therapeutic Response to HER2/PD-1 Dual Blockade in HER2-Positive Gastric Cancer.” Digestion (2026). PMID: 42479643 ↗
L3COHORTCited in: Fertility-Sparing Surgery - [46]
Karaoglan BB, Terán E, Mascaró Baselga P et al.. “Survival Outcomes in ERBB2-Low vs ERBB2-Null Advanced Gastric Cancer.” JAMA network open (2026). PMID: 42479431 ↗
L3RETROSPECTIVE_COHORTCited in: Fertility-Sparing Surgery - [47]
Wei Y, Tian Y, Liu X et al.. “Residual tumor deposits after neoadjuvant therapy and 3-year survival outcomes in gastric cancer: a single-center retrospective cohort study.” World journal of surgical oncology (2026). PMID: 42477761 ↗
L4RETROSPECTIVE_COHORTCited in: Fertility-Sparing Surgery - [48]
Gao X, Han W, Lu L et al.. “Incidence, risk factors and tumor spectrum of second primary cancers after gastric cancer: a multicenter cohort study with long-term follow-up.” BMC medicine (2026). PMID: 42477705 ↗
L3COHORTCited in: Fertility-Sparing Surgery - [49]
Sagawa T, Umehara K, Izumi M et al.. “Real-world implementation of a standardized administration protocol for zolbetuximab-associated nausea and vomiting: a retrospective supportive-care cohort study.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2026). PMID: 42477146 ↗
L4RETROSPECTIVE_COHORTCited in: Fertility-Sparing Surgery - [50]
Díaz Del Arco C, Fernández Aceñero MJ, Sánchez Pernaute A et al.. “Combined quantitative-anatomical assessment of metastatic lymph nodes refines prognostic stratification in resected gastric cancer.” Surgical oncology (2026). PMID: 42475787 ↗
L3RETROSPECTIVE_COHORTCited in: Fertility-Sparing Surgery - [51]
Yanagimoto Y, Yamamoto K, Yamamoto K et al.. “Zolbetuximab-induced gastric mucosal injury and hypoalbuminemia: a mechanism-informed clinical analysis.” Cancer chemotherapy and pharmacology (2026). PMID: 42474748 ↗
L3COHORTCited in: Fertility-Sparing Surgery - [52]
Fujii Y, Hisamori S, Hoshino N et al.. “Comparison of minimally invasive surgery and open surgery following chemotherapy for cStage IVb gastric cancer: a multicenter retrospective cohort study.” Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2026). PMID: 42474616 ↗
L3RETROSPECTIVE_COHORTCited in: Fertility-Sparing Surgery - [53]
Skogar ML, Lindblad M, Linder G. “Obesity and outcomes after esophagectomy: A nationwide population-based cohort study.” Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society (2026). PMID: 42473743 ↗
L3COHORTCited in: Fertility-Sparing Surgery - [54]
Gokcek S, Kanbur B, Yetginoglu O et al.. “Prognostic value of the lung immune prognostic index in metastatic gastric cancer: a single-center retrospective cohort study.” Future oncology (London, England) (2026). PMID: 42469963 ↗
L3RETROSPECTIVE_COHORTCited in: Fertility-Sparing Surgery - [55]
Kitagawa Y, Takeuchi H, Takagi Y et al.. “Sentinel node mapping for gastric cancer: a prospective multicenter trial in Japan.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2013). PMID: 24019550 ↗
L2NON_RANDOMIZED_TRIALCited in: Sentinel Lymph Node Mapping - [56]
Liang Y, Yan Z, Wei M et al.. “Indocyanine green fluorescence-guided proximal margin identification in laparoscopic distal gastrectomy: a randomized clinical trial.” Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2026). PMID: 41489800 ↗
L1RCTCited in: Sentinel Lymph Node Mapping - [57]
Zhong Q, Wu D, Liu ZY et al.. “Long-term oncological outcomes of indocyanine green fluorescence imaging-guided laparoscopic lymphadenectomy for gastric cancer: 5-year outcomes from the FUGES-012 randomized clinical trial.” BMC medicine (2025). PMID: 40859341 ↗
L1RCTCited in: Sentinel Lymph Node Mapping - [58]
Jeong SH, Min JS, Kim YW et al.. “Clinicopathological Factors Affecting Stomach Preservation Following Laparoscopic Sentinel Node Navigation Surgery in Patients with Early Gastric Cancer: A Secondary Analysis of the Multicenter Randomized Phase III SENORITA Trial.” Annals of surgical oncology (2025). PMID: 40117015 ↗
L1RCTCited in: Sentinel Lymph Node Mapping - [59]
Yan Z, Wei M, Zhang T et al.. “Vagus Nerve Preservation for Early Distal Gastric Cancer With Monitoring and Indocyanine Green Labeling: A Randomized Clinical Trial.” JAMA surgery (2025). PMID: 39535740 ↗
L1RCTCited in: Sentinel Lymph Node Mapping - [60]
Park SH, Kim YW, Min JS et al.. “Feasibility of Regional Lymphadenectomy for Stomach-Preserving Surgery in Early Gastric Cancer Omitting Sentinel Node Navigation: A Post Hoc Analysis of the SENORITA Trial.” Annals of surgical oncology (2024). PMID: 39085549 ↗
L4RCTCited in: Sentinel Lymph Node Mapping - [61]
Tian Y, Pang Y, Yang P et al.. “Effect of carbon nanoparticle suspension injection versus indocyanine green tracer in guiding lymph node dissection during radical gastrectomy (FUTURE-01): a randomized clinical trial.” International journal of surgery (London, England) (2025). PMID: 38954670 ↗
L1RCTCited in: Sentinel Lymph Node Mapping - [62]
Park SH, Chung SY, Lee JH et al.. “Feasibility of intraoperative pathologic examination for sentinel lymph nodes during sentinel node navigation surgery in early gastric cancer: results of pathologic protocol for SENORITA trial.” Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2024). PMID: 38647977 ↗
L4RCTCited in: Sentinel Lymph Node Mapping - [63]
Huang ZN, Tang YH, Zhong Q et al.. “Assessment of Laparoscopic Indocyanine Green Tracer-guided Lymphadenectomy After Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: A Randomized Controlled Trial.” Annals of surgery (2024). PMID: 38375670 ↗
L1RCTCited in: Sentinel Lymph Node Mapping - [64]
Zhao L, Zhao J, Wang Y et al.. “A randomized trial of combined indocyanine green and endoscopic ultrasound for lymph node evaluation in gastric cancer surgery.” Quantitative imaging in medicine and surgery (2025). PMID: 41081114 ↗
L1RCTCited in: Sentinel Lymph Node Mapping - [65]
Kruszyna B, Orzechowska D, Setlak Z et al.. “Efficacy of near-infrared indocyanine green imaging in D2 lymphadenectomy for gastric cancer: A systematic review and meta-analysis comparing eastern and western cohorts.” Surgical oncology (2026). PMID: 42202594 ↗
L2SR_COHORTCited in: Sentinel Lymph Node Mapping - [66]
Fernandes MHF, Valério-Alves AP, Colares RA et al.. “Indocyanine green-guided lymphadenectomy in gastric cancer after neoadjuvant chemotherapy: A systematic review and meta-analysis.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2025). PMID: 41092717 ↗
L2SR_COHORTCited in: Sentinel Lymph Node Mapping - [67]
Slim N, Anbu D, Darzi A et al.. “The use of indocyanine green and near-infrared fluorescence in the detection of metastatic lymph nodes during oesophageal and gastric cancer resection: a systematic review and meta-analysis.” Surgical endoscopy (2025). PMID: 40251309 ↗
L4SR_COHORTCited in: Sentinel Lymph Node Mapping - [68]
Peristeri DV, Raptis DN, Mantzoros I et al.. “Clinical Value of Fluorescent Lymphography with Indocyanine Green During Robotic Surgery for Gastric Cancer in Guided Lymph Node Dissection: A Systematic Review and Meta-Analysis.” Journal of personalized medicine (2026). PMID: 42188338 ↗
L2SR_COHORTCited in: Sentinel Lymph Node Mapping - [69]
Mourdi N, Wu Y, Su Y et al.. “The role of indocyanine green in the intraoperative navigation of gastric cancer surgery: a systematic review and meta-analysis.” BMC cancer (2025). PMID: 41299421 ↗
L4SR_COHORTCited in: Sentinel Lymph Node Mapping - [70]
Fan Y, Zhang C, Liang P et al.. “Indocyanine Green-Guided Lymphadenectomy During Robot-Assisted Pylorus and Vagus Nerve Preserving Gastrectomy for Early Gastric Cancer: A Single-Centre Study.” The international journal of medical robotics + computer assisted surgery : MRCAS (2025). PMID: 41044819 ↗
L2NON_RANDOMIZED_TRIALCited in: Sentinel Lymph Node Mapping - [71]
Van Du N, Anh Tuan N, Ngoc Cuong L. “Comparative study of ICG and non-ICG-guided laparoscopic gastrectomy for gastric cancer: a propensity score-matched analysis at a single center.” BMJ surgery, interventions, & health technologies (2025). PMID: 40051652 ↗
L2NON_RANDOMIZED_TRIALCited in: Sentinel Lymph Node Mapping - [72]
Salobir J, Horvat G, Trotovšek B et al.. “Safe Introduction of Robotic Gastrectomy Facilitated by ICG-Guided Lymphography.” Journal of clinical medicine (2026). PMID: 42355706 ↗
L4PROSPECTIVE_COHORTCited in: Sentinel Lymph Node Mapping - [73]
Park SH, Lim DH, Sohn TS et al.. “A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial☆.” Annals of oncology : official journal of the European Society for Medical Oncology (2020). PMID: 33278599 ↗
L1RCTCited in: Adjuvant Therapy Triggers (Post-op Risk Criteria), Outcomes by Stage and Approach - [74]
De Vita F, Giuliani F, Orditura M et al.. “Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study).” Annals of oncology : official journal of the European Society for Medical Oncology (2007). PMID: 17525087 ↗
L1RCTCited in: Adjuvant Therapy Triggers (Post-op Risk Criteria) - [75]
Park SH, Sohn TS, Lee J et al.. “Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 25559811 ↗
L1RCTCited in: Adjuvant Therapy Triggers (Post-op Risk Criteria) - [76]
Fuchs CS, Niedzwiecki D, Mamon HJ et al.. “Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance).” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2017). PMID: 28976791 ↗
L1RCTCited in: Adjuvant Therapy Triggers (Post-op Risk Criteria) - [77]
Sasako M, Sakuramoto S, Katai H et al.. “Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PMID: 22010012 ↗
L1RCTCited in: Adjuvant Therapy Triggers (Post-op Risk Criteria) - [78]
Lee J, Lim DH, Kim S et al.. “Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PMID: 22184384 ↗
L1RCTCited in: Adjuvant Therapy Triggers (Post-op Risk Criteria) - [79]
Sada YH, Smaglo BG, Tan JC et al.. “Prognostic Value of Nodal Response After Preoperative Treatment of Gastric Adenocarcinoma.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 30787129 ↗
L3RETROSPECTIVE_COHORTCited in: Adjuvant Therapy Triggers (Post-op Risk Criteria), Outcomes by Stage and Approach - [80]
Wang JT, Li H, Zhang H et al.. “Intratumoral IL17-producing cells infiltration correlate with antitumor immune contexture and improved response to adjuvant chemotherapy in gastric cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2019). PMID: 30445581 ↗
L4PROSPECTIVE_COHORTCited in: Adjuvant Therapy Triggers (Post-op Risk Criteria) - [81]
Jiang Y, Wang H, Wu J et al.. “Noninvasive imaging evaluation of tumor immune microenvironment to predict outcomes in gastric cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2020). PMID: 32240794 ↗
L2PROSPECTIVE_COHORTCited in: Adjuvant Therapy Triggers (Post-op Risk Criteria) - [82]
Schwartz GK, Winter K, Minsky BD et al.. “Randomized phase II trial evaluating two paclitaxel and cisplatin-containing chemoradiation regimens as adjuvant therapy in resected gastric cancer (RTOG-0114).” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19273696 ↗
L2RCT_PHASE2Cited in: Adjuvant Therapy Triggers (Post-op Risk Criteria) - [83]
Zhang LK, Shang-Guan ZX, Zheng HL et al.. “Association of comprehensive inflammatory-metabolic status and perioperative outcomes in gastric cancer: insights from four randomized controlled trials.” ESMO open (2026). PMID: 41962309 ↗
L1RCTCited in: Adjuvant Therapy Triggers (Post-op Risk Criteria), Intraoperative Considerations and Complications - [84]
McNair AG, Brookes ST, Davis CR et al.. “Communicating the results of randomized clinical trials: do patients understand multidimensional patient-reported outcomes?” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2010). PMID: 20065187 ↗
L1RCTCited in: Intraoperative Considerations and Complications - [85]
Sasako M, Sano T, Yamamoto S et al.. “D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer.” The New England journal of medicine (2008). PMID: 18669424 ↗
L1RCTCited in: Intraoperative Considerations and Complications - [86]
Menegat BLRS, Menegat ALRS, Dantas CR et al.. “Safety and feasibility of subtotal gastrectomy compared with completion total gastrectomy for remnant gastric cancer: A systematic review and meta-analysis.” Surgical oncology (2026). PMID: 42248045 ↗
L4SR_COHORTCited in: Intraoperative Considerations and Complications - [87]
Shen ZY, Wang ZQ, Yu TC et al.. “Robotic versus laparoscopic gastrectomy for gastric cancer: a systematic review and meta-analysis of perioperative outcome and long-term survival.” Journal of robotic surgery (2026). PMID: 42010147 ↗
L2SR_COHORTCited in: Intraoperative Considerations and Complications - [88]
Miki Y, Bito T, Makuuchi R et al.. “Limited lymphadenectomy for elderly patient with gastric cancer: a systematic review and meta-analysis.” Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2026). PMID: 41879959 ↗
L2SR_COHORTCited in: Intraoperative Considerations and Complications - [89]
Yang D, Liu H, Xia Y et al.. “Dynamic machine learning model integrating resting energy expenditure for predicting postoperative complications after gastrectomy for gastric cancer.” Journal of cancer research and clinical oncology (2026). PMID: 42107025 ↗
L2PROSPECTIVE_COHORTCited in: Intraoperative Considerations and Complications - [90]
Rayyan Y, Odeh N, Theeb L et al.. “Prognostic role of C-reactive protein-albumin-lymphocyte (CALLY) index in gastrointestinal malignancies: a systematic review and meta-analysis.” BMC gastroenterology (2026). PMID: 41963801 ↗
L2SR_COHORTCited in: Intraoperative Considerations and Complications - [91]
Lee E, Yoo M, Jeon D et al.. “Impact of Combined Frailty and Sarcopenia on Postoperative Outcomes and Survival in Elderly Gastric Cancer Patients Undergoing Gastrectomy.” Journal of gastric cancer (2026). PMID: 42411167 ↗
L4COHORTCited in: Intraoperative Considerations and Complications - [92]
Lim D, Han J, Noh J et al.. “Comparison of textbook outcomes and postoperative pain trajectories between reduced-port and conventional robotic distal gastrectomy: a cumulative sum (CUSUM)-adjusted propensity score-matched analysis.” Journal of robotic surgery (2026). PMID: 42298275 ↗
L3RETROSPECTIVE_COHORTCited in: Intraoperative Considerations and Complications - [93]
Matsumoto Y, Terashima M, Fujiya K et al.. “Association between the inflow pattern of the left gastric vein and postoperative pancreatic fistula after laparoscopic gastrectomy.” Surgical endoscopy (2026). PMID: 42265294 ↗
L4COHORTCited in: Intraoperative Considerations and Complications - [94]
Fujita S, Harada H, Okuno K et al.. “Pancreas-contactless open gastrectomy for gastric cancer and postoperative pancreatic complications: A retrospective cohort study.” Surgical oncology (2026). PMID: 42250430 ↗
L3RETROSPECTIVE_COHORTCited in: Intraoperative Considerations and Complications - [95]
Sakurazawa N, Kakinuma D, Hagiwara N et al.. “Trapezoidal tunnel intracorporeal esophagogastric anastomosis technique in laparoscopic-assisted proximal gastrectomy: technical notes and preliminary experience.” World journal of surgical oncology (2026). PMID: 42219492 ↗
L4COHORTCited in: Intraoperative Considerations and Complications - [96]
Jang A, Jeong O. “Association between preoperative quality of life (QoL) and postoperative complications after gastrectomy for gastric carcinoma.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2026). PMID: 42177387 ↗
L3COHORTCited in: Intraoperative Considerations and Complications - [97]
Sanberg J, Noordman BJ, Lindblad M et al.. “Robot-assisted versus laparoscopic total gastrectomy: a western high-volume tertiary referral center experience.” Journal of robotic surgery (2026). PMID: 42156604 ↗
L3RETROSPECTIVE_COHORTCited in: Intraoperative Considerations and Complications - [98]
Takahashi K, Fujiya K, Terashima M et al.. “Comparison of long-term outcomes of robotic gastrectomy and laparoscopic gastrectomy using the modified age-adjusted Charlson Comorbidity Index.” Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2026). PMID: 42113328 ↗
L3COHORTCited in: Intraoperative Considerations and Complications - [99]
Yan Z, Zhao R, Ouyang J et al.. “Association between additional operation timing and perioperative outcomes after noncurative endoscopic submucosal dissection for early gastric cancer.” Surgery (2026). PMID: 42105700 ↗
L3RETROSPECTIVE_COHORTCited in: Intraoperative Considerations and Complications - [100]
Zhu C, Wang Y, Ma W et al.. “Efficacy and safety of home enteral nutritional support in postoperative gastric cancer patients: A systematic review and meta-analysis.” Clinical nutrition (Edinburgh, Scotland) (2026). PMID: 41895151 ↗
L1SR_MA_RCTCited in: Postoperative Recovery and ERAS - [101]
Datta J, McMillan MT, Shang EK et al.. “Omission of adjuvant therapy after gastric cancer resection: development of a validated risk model.” Journal of the National Comprehensive Cancer Network : JNCCN (2015). PMID: 25964639 ↗
L5OTHERCited in: Postoperative Recovery and ERAS - [102]
Hu HM, Zhou HY, Guo LL et al.. “Enhanced recovery after surgery in laparoscopic radical gastrectomy for gastric cancer: efficacy, safety, meta-analysis.” Biomedical engineering online (2026). PMID: 41664176 ↗
L1SR_MA_RCTCited in: Postoperative Recovery and ERAS - [103]
Liu W, He L, Yin C et al.. “Enhanced recovery after gastrectomy: updated Meta-analysis of 27 randomized trials (2018-2025).” BMC surgery (2025). PMID: 41354909 ↗
L1SR_MA_RCTCited in: Postoperative Recovery and ERAS - [104]
Mohajeri L, Daghayeghi R, Rostami N et al.. “Early oral feeding after laparoscopic total gastrectomy in gastric cancer patients: a meta-analysis of randomized controlled trials and cohort studies.” BMC gastroenterology (2025). PMID: 41068719 ↗
L1SR_MA_RCTCited in: Postoperative Recovery and ERAS - [105]
Shanshan W, Lian W, Lu D et al.. “Best practices for home nutritional management in postoperative gastric cancer patients: an evidence summary.” BMC cancer (2025). PMID: 40883694 ↗
L1SR_MA_RCTCited in: Postoperative Recovery and ERAS - [106]
Pan S, Wang G. “Perioperative multimodal behavioral optimization improves recovery and long-term outcomes after curative gastrectomy: a randomized controlled trial.” Surgical endoscopy (2026). PMID: 41787085 ↗
L1RCTCited in: Postoperative Recovery and ERAS - [107]
Sun Y, Tian Y, Cao S et al.. “Supervised Multimodal Prehabilitation and Clinical Outcomes in Older Patients With Frailty and Gastric Cancer: The GISSG+2201 Randomized Clinical Trial.” JAMA surgery (2026). PMID: 41604182 ↗
L1RCTCited in: Postoperative Recovery and ERAS - [108]
Lee HJ, Kim J, Koo BW et al.. “Survey of Perioperative Practices in Gastric Cancer Surgery for Establishing an Enhanced Recovery After Surgery Program Across 10 Tertiary Hospitals in South Korea.” Journal of gastric cancer (2025). PMID: 40631472 ↗
L1RCTCited in: Postoperative Recovery and ERAS - [109]
Lee HJ, Kim J, Yoon SH et al.. “Effectiveness of ERAS program on postoperative recovery after gastric cancer surgery: a randomized clinical trial.” International journal of surgery (London, England) (2025). PMID: 40072360 ↗
L1RCTCited in: Postoperative Recovery and ERAS - [110]
Tian Y, Cao S, Li L et al.. “Three-year Survival Outcomes of Patients With Enhanced Recovery After Surgery Versus Conventional Care in Laparoscopic Distal Gastrectomy: The GISSG1901 Randomized Clinical Trial.” Annals of surgery (2024). PMID: 39660451 ↗
L1RCTCited in: Postoperative Recovery and ERAS - [111]
Weindelmayer J, Mengardo V, Ascari F et al.. “Prophylactic Drain Placement and Postoperative Invasive Procedures After Gastrectomy: The Abdominal Drain After Gastrectomy (ADIGE) Randomized Clinical Trial.” JAMA surgery (2025). PMID: 39602143 ↗
L1RCTCited in: Postoperative Recovery and ERAS - [112]
Choi CI, Park JK, Chung JH et al.. “The application of enhanced recovery after surgery protocol after distal gastrectomy for patients with gastric cancer: a prospective randomized clinical trial.” Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract (2024). PMID: 38538479 ↗
L1RCTCited in: Postoperative Recovery and ERAS - [113]
Lee JS, Hu HM, Edelman AL et al.. “New Persistent Opioid Use Among Patients With Cancer After Curative-Intent Surgery.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2017). PMID: 29048972 ↗
L5OTHERCited in: Postoperative Recovery and ERAS - [114]
. “[Chinese clinical practice guideline for the laparoscopic endoscopic cooperative surgery in gastrointestinal tumor (2025 Shenzhen)].” Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery (2025). PMID: 39971545 ↗
L1GUIDELINECited in: Postoperative Recovery and ERAS - [115]
Wu J, Zhang L, Ji Y et al.. “Effects of enhanced recovery after surgery nursing combined with early enteral nutrition on Gastrointestinal function recovery after radical gastrectomy.” Langenbeck's archives of surgery (2025). PMID: 41307576 ↗
L1RCTCited in: Postoperative Recovery and ERAS - [116]
Guo S, Lin XP, Jin XR et al.. “Effect of the thumbtack needle on gastrointestinal function recovery after laparoscopic radical gastrectomy for gastric cancer with the concept of enhanced recovery after surgery: a randomized controlled trial.” Frontiers in surgery (2025). PMID: 41050349 ↗
L1RCTCited in: Postoperative Recovery and ERAS - [117]
. “RETRACTION: Effects of Enhanced Recovery After Surgery Nursing Program on the Surgical Site Wound Infection and Postoperative Complications in Patients of Gastric Cancer: A Meta-Analysis.” International wound journal (2025). PMID: 42118060 ↗
L2SR_COHORTCited in: Postoperative Recovery and ERAS - [118]
Li HY, Liu Y, Cui WX et al.. “Enhanced recovery after surgery in gastric cancer surgery: Systematic review and meta-analysis of perioperative indwelling drainage tube use.” World journal of gastrointestinal surgery (2025). PMID: 41178892 ↗
L1SR_MA_RCTCited in: Postoperative Recovery and ERAS - [119]
Chau I, Norman AR, Cunningham D et al.. “The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials.” Annals of oncology : official journal of the European Society for Medical Oncology (2009). PMID: 19164454 ↗
L1SR_MA_RCTCited in: Outcomes by Stage and Approach - [120]
Janjigian YY, Shitara K, Ajani JA et al.. “Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649.” Annals of oncology : official journal of the European Society for Medical Oncology (2026). PMID: 41687718 ↗
L1RCTCited in: Outcomes by Stage and Approach - [121]
Liu R, Zhao J, Zhang R et al.. “Anbenitamab in previously treated HER2-positive gastric cancer (KC-WISE): prespecified interim analysis of a randomized, phase III clinical trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2026). PMID: 41571045 ↗
L1RCTCited in: Outcomes by Stage and Approach - [122]
Sakai D, Kadowaki S, Kawabata R et al.. “Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40408613 ↗
L1RCTCited in: Outcomes by Stage and Approach - [123]
Li J, Qin S, Xu J et al.. “Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2016). PMID: 26884585 ↗
L1RCTCited in: Outcomes by Stage and Approach - [124]
Lee CK, Kim HS, Jung M et al.. “Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37883723 ↗
L1RCTCited in: Outcomes by Stage and Approach - [125]
Kim HS, Kim HJ, Kim SY et al.. “Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis.” Annals of oncology : official journal of the European Society for Medical Oncology (2013). PMID: 23942775 ↗
L2SR_COHORTCited in: Outcomes by Stage and Approach - [126]
Singh PP, Singh S. “Statins are associated with reduced risk of gastric cancer: a systematic review and meta-analysis.” Annals of oncology : official journal of the European Society for Medical Oncology (2013). PMID: 23599253 ↗
L2SR_COHORTCited in: Outcomes by Stage and Approach - [127]
Okines AFC, Norman AR, McCloud P et al.. “Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2009). PMID: 19474114 ↗
L2SR_COHORTCited in: Outcomes by Stage and Approach - [128]
Pietrantonio F, Randon G, Di Bartolomeo M et al.. “Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials.” ESMO open (2021). PMID: 33460964 ↗
L1SR_MA_RCTCited in: Outcomes by Stage and Approach - [129]
Hegewisch-Becker S, Mendez G, Chao J et al.. “First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 38723227 ↗
L2RCT_PHASE2Cited in: Outcomes by Stage and Approach
Backlinks
- ← Gastric Cancer (Detailed)
- ← Gastric Cancer Radiation Management (Detailed)
- ← Gastric Cancer Palliative Care
- ← Gastric Cancer Palliative Care (Detailed)
- ← Gastric Cancer Recurrent and Metastatic Disease (Detailed)
- ← Gastric Cancer Systemic Therapy (Detailed)
- ← Gastric Cancer Surveillance and Follow-up
- ← Gastric Cancer Radiation Management
- ← Gastric Cancer Recurrent and Metastatic Disease
- ← Gastric Cancer Surveillance and Follow-up (Detailed)